All atypical antipsychotics used off label to treat dementia-related psychosis included in the analysis were associated with greater odds of mortality, cerebrovascular adverse events, and discontinuations due to adverse events compared with placebo

Compared to placebo, olanzapine, and aripiprazole demonstrated a small, non-significant improvement in symptoms of psychosis

Although olanzapine improved psychosis symptoms, it was associated with a greater risk of mortality and cerebrovascular adverse events than placebo